47 results about "T-Cell Antigen Receptors" patented technology

The present invention relates to monoclonal antibodies which recognize defined regions of the T-cell receptor (TCR). In a specific embodiment, the invention provides monoclonal antibodies which are reactive with a constant region of the alpha chain of the TCR. In particular embodiments, the invention relates to two monoclonal antibodies, termed alphaF1 and alphaF2, which react with two different epitopes on the framework region of the alpha monomer of the TCR molecule. In another specific embodiment, the invention is directed to monoclonal antibodies reactive with a variable region of the beta chain of the TCR. In particular, the invention provides two monoclonal antibodies, termed W112 and 2D1, which react with beta chain variable regions Vbeta5.3 and Vbeta8.1, respectively. In another specific embodiment, the invention is directed to monoclonal antibodies reactive with a variable region of the delta chain of the TCR. In particular, the invention provides monoclonal antibody deltaTCS1, isotype IgG2a. The monoclonal antibodies of the invention have value in diagnosis and therapy and are useful tools for study of the immune system.

The present invention has objects to provide a novel human T-cell population having both cytotoxic and immunosuppressive activities, and to a method for preparing the same. The above objects are attained by providing a human T-cell population which is obtainable by coculturing mononuclear cells, collected from human blood, with stroma cells and which has the following features:(1) being positive for CD3, CD25, CD28 and T-cell antigen receptor αβ;(2) essentially consisting of three groups of a CD4 positive and CD8 positive (CD4+CD8+) T-cell group, a CD4 positive and CD8 dimly positive (CD4+CD8dim) T-cell group, and a CD4 negative and CD8 positive (CD4−CD8+) T-cell group;(3) exerting a cytotoxic activity against the cocultured stroma cells; and(4) exerting an immunosuppressive activity against activated T cells.

The invention discloses a method for simultaneously sequencing a multi-sample CDR3 (complementary determining region 3) receptor library with a high flux, comprising the following steps of: only designing one set of V-gene family upstream primers in the variable region of a TCR (T cell antigen receptor) or BCR (B cell antigen receptor) chain according to the homology of the V-gene family, then designing C or J gene characteristic downstream primers of the TCR or BCR chain as many as samples and suitable for being paired with the upstream primers, amplifying each sample by one characteristic downstream primer and the same set of upstream primers to obtain a CDR3 region of the TCR or BCR, then mixing all the amplified samples to be a to-be-sequenced sample library, finally sequencing, wherein the characteristic downstream primers are designed by different ATCG basic group compositions. The CDR3 sequences of multiple samples can be simultaneously sequenced by operating one high-flux sequencing program via the method for simultaneously sequencing a multi-sample CDR3 receptor library with a high flux disclosed by the invention, so that the high-flux sequencing cost is greatly decreased. Thus, a high-flux sequencing technology has a wide application value in a sequencing research of a CDR3 receptor library.